Tom Powles

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

Tom Powles
Mar 31, 2025, 18:51 | Blog
Insights from GUtrends25 on Urothelial Cancer Treatment by Tom Powles
Tom Powles, Professor at the University of London, shared a post on X: "At GUtrends25…
Mar 30, 2025, 14:17 | Blog
Tom Powles presented uromigos Score in 3 scenarios at GUtrends25
Tres Uramigas shared a post on X: "Ready for the second day? GUtrends25 !  Today…
Feb 20, 2025, 09:43 | Insight
Neeraj Agarwal: No OS or PFS benefit with SG in pretreated mUC bladder cancer
Neeraj Agarwal, Presidential Endowed Chair of Cancer Research at  Huntsman Cancer Institute, shared a post…
Feb 16, 2025, 19:10 | Insight
Highlights by Tom Powles from ASCO GU25
At ASCO GU 2025, Professor Tom Powles, Professor at the University of London, highlighted key…
Feb 16, 2025, 04:58 | Blog
Tom Powles: TROPICS4 - sacituzimab govitecan vs chemo in pretreated urothelial carcinoma
Tom Powles, Professor at the University of London, shared a post on X: "TROPICS4 sacituzimab…
Feb 16, 2025, 04:20 | Societies
Highlights From Day 3 of ASCOGU25
The ASCO Genitourinary Cancers Symposium (ASCOGU25) is an annual event organized by the American Society of Clinical…
Feb 15, 2025, 22:55 | Societies
Highlights From Day 2 of ASCOGU25
The ASCO Genitourinary Cancers Symposium (ASCOGU25) is an annual event organized by the American Society of Clinical Oncology…
Feb 14, 2025, 20:30 | Societies
Highlights From Day 1 of ASCOGU25
The ASCO Genitourinary Cancers Symposium (ASCOGU25) is an annual event organized by the American Society…
Feb 13, 2025, 09:30 | Insight
Petros Grivas: TROPiCS04 P3 trial data has been published
Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, shared…
Feb 8, 2025, 07:02 | Blog
Tom Powles: Bladder cancer highlights at ASCOGU25
Tom Powles, Professor at the University of London and Director of Barts Cancer Centre, shared…
Feb 2, 2025, 17:00 | Insight
Guru Sonpavde: Exciting trials to look for at ASCO GU25
Guru Sonpavde, Phase I Clinical Trials Director at Advent Health Central Florida and the Chair of…
Jan 28, 2025, 06:14 | Blog
Shilpa Gupta: Always delighted to listen to the one and only Tom Powles
Shilpa Gupta, Director of Genitourinary Oncology at Cleveland Clinic, posted on X: "AUC3 Day 2…
Jan 27, 2025, 15:58 | Blog
Tom Powles: Bladder sparing approaches after EVP is likely to be the SoC in MIBC
Tom Powles, Professor at the University of London, shared a post on X: "The muscle…
Jan 26, 2025, 12:10 | Blog
Tom Powles: Perioperative durvalumab + ctDNA are changing the muscle invasive bladder cancer
Tom Powles, Professor at the University of London, shared on X: "The muscle invasive bladder…
Jan 26, 2025, 06:40 | Insight
Highlights from AUC3 by Shilpa Gupta
The Advanced Urologic Cancer Consensus Conference (AUC3), held on January 23-24, 2025, was a dynamic…
Jan 11, 2025, 14:16 | Science
Tom Powles: Positive R3 trial for PD-1 in Non-Muscle Invasive Bladder Cancer
Tom Powles, Professor at the University of London, posted on X: "Big news. A positive…
Dec 30, 2024, 06:41 | Insight
Tom Powles: TIGIT and LAG3 targets have been explored
Tom Powles, Professor at the University of London, posted the following on X: “TIGIT and…
Dec 29, 2024, 08:34 | Blog
Tian Zhang: Always enjoy seeing Toni Choueiri top 10 GU papers of the year
Tian Zhang, Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center,…
Dec 27, 2024, 17:02 | Insight
Toni Choueiri: Top 10 GU Bladder/Kidney Cancer Trials for 2024
Toni Choueiri, Director of the Lank Center for GU Oncology at Dana-Farber Cancer Institute, shared…
Dec 17, 2024, 23:36 | Blog
Durvalumab and chemotherapy improves survival in MIBC - Uro Today
UroToday.com shared  a post on X: "NIAGARA trial shows durvalumab + chemotherapy improves survival in…
Dec 10, 2024, 18:06 | Blog
Roberto Iacovelli: Fantastic presentation by Renu Eapen on the role of surgery for MIBC
Roberto Iacovelli, Medical Oncologist at Gemelli Polyclinic Foundation IRCCS, posted the following on X: “Fantastic…
Dec 10, 2024, 13:49 | Blog
Tom Powles: Sacituzumab govitecan vs chemotherapy in heavily pretreated UC
Tom Powles, Professor at the University of London, posted the following on X: “1/3 TROPICS-4: Sacituzumab govitecan…
Dec 10, 2024, 13:18 | Societies
Best of ESMO Asia 2024
ESMO Asia is an annual congress focused on multidisciplinary oncology in the Asian region. ESMO…
Dec 9, 2024, 14:39 | Blog
Tom Powles: Terry Friedlander highlights multiple factors why SG did not beat chemotherapy in UC
 Tom Powles, Professor at the University of London, shared a post on X: "TROPICS4 discusses…
Dec 9, 2024, 04:32 | Societies
Highlights from Day 3 of ESMO Asia 2024
ESMO Asia was an annual congress focused on multidisciplinary oncology in the Asian region. ESMO…
Dec 8, 2024, 12:04 | Blog
Roberto Iacovelli: Tom Powles represented NIAGARA results for perioperative therapy of MIBC at ESMOAsia24
Roberto Iacovelli, Medical oncologist at Fondazione Policlinico Gemelli IRCCS in Rome, shared a post on…
Dec 8, 2024, 07:13 | Blog
Petros Grivas: Great to present TROPiCS04 trial at ESMOAsia24
Petros Grivas, Clinical Director of the Genitourinary Cancers Program at the University of Washington, reshared…
Dec 8, 2024, 06:30 | Insight
Tom Powles: Cisplatin or Carboplatin-Based Chemotherapy with Pembrolizumab in Advanced Urothelial Cancer
Tom Powles, Director of Barts Cancer Centre, shared a recent article on X: "While EVP…
Dec 8, 2024, 06:21 | Societies
Highlights from Day 2 of ESMO Asia 2024
ESMO Asia is an annual congress focused on multidisciplinary oncology in the Asian region. ESMO…
Dec 8, 2024, 04:08 | Blog
Tom Powles: Belzutifan attractive pretreated clear cell RCC
Tom Powles, Professor at the University of London, shared a post on X: "Belzutifan attractive…
Dec 7, 2024, 19:49 | Blog
Tom Powles: Impressive bladder cancer sessions for Asian subsets at ESMO Asia 2024
Tom Powles, The Director of Barts Cancer Centre, a CRUK Major Cancer Centre, posted on…
Dec 7, 2024, 13:57 | Blog
Highlights from Day 1 of ESMO Asia 2024
ESMO Asia is an annual congress focused on multidisciplinary oncology in the Asian region. ESMO…
Nov 27, 2024, 12:55 | Blog
Tom Powles: Truqap Combination Improves RPFS in PTEN-Deficient Prostate Cancer
Tom Powles, Director of Barts Cancer Centre, shared a post on X: "Positive PFS results for…
Nov 17, 2024, 09:07 | Blog
Sumanta K. Pal: Always learning something new from Tom Powles
Sumanta K. Pal, Medical Oncologist at the City of Hope Comprehensive Cancer Center, shared a…
Nov 8, 2024, 18:55 | Insight
Regina Barragan-Carrillo: First and second - line treatments in metastatic renal cell carcinoma
Regina Barragan-Carrillo, Postdoctoral fellow at the Genitourinary Clinic at the Medical Oncology and Medical Therapeutics…
Nov 8, 2024, 13:58 | Blog
Rashad Nawfal: Our work on the landscape of subsequent therapies in perioperative Immuno-oncology trials
Rashad Nawfal, Postdoctoral Research Fellow at Dana Farber Cancer Institute, shared on X about recent…
Nov 6, 2024, 12:05 | Blog
Karl Semaan: Landscape of subsequent therapies in perioperative immunotherapy trials
Karl Semaan, Postdoctoral Oncology Research Fellow at Dana-Farber Cancer Institute, posted on X about recent…
Nov 5, 2024, 17:40 | Blog
Tom Powles: First-Line UC Trials - Ipi/Nivo Fails on OS, Durva/Treme Shows Potential in PD-L1 Positive Patients
Tom Powles, Director of Barts Cancer Centre, shared a post on X: "Just out. Ipi/nivo…
Nov 5, 2024, 01:12 | Blog
Shilpa Gupta: NIAGARA trial insights on bladder cancer treatment
Shilpa Gupta shared a post by UroToday on X, adding the following: “Had a great…
Nov 3, 2024, 12:59 | Insight
Uromigos Live24 panel on novel ADCs in urothelial carcinoma
Uromigos shared a post on X: “Don't get spooked by new data - watch the…
Oct 28, 2024, 09:59 | Blog
Tom Powles: Phase 1b data with the HIF2a inhibitor casdatifan in clear cell patients
Tom Powles, Director of Barts Cancer Centre, shared a post on X: "Phase 1b data…
Oct 19, 2024, 16:37 | Drugs
Gilead Sciences has voluntarily withdrawn Trodelvy from the U.S. market
Gilead Sciences announced the voluntary withdrawal of its drug Trodelvy for bladder cancer after it…
Oct 18, 2024, 19:24 | Blog
Bladder preservation in muscle-invasive bladder cancer - 57th Urology Course
57th Urology Course posted on LinkedIn: "Debate: Bladder preservation in muscle-invasive bladder cancer. Bladder preservation…
Oct 13, 2024, 10:59 | Insight
Alessandro Di Federico: Honored to have our work highlighted in this months issue of Annals of Oncology
Alessandro Di Federico shared a post by Annals of Oncology on X, adding: "Honored to have…
Oct 10, 2024, 18:35 | Blog
Chandler Park: Enjoyed reviewing the data from the top GU oncologists from around the world at Uromigos Live 24
Chandler Park posted the following on LinkedIn: “Thank you Brian Rini, Tom Powles, The Uromigos…
Oct 10, 2024, 14:16 | Dialogues
NIAGARA Study Insights: Durvalumab and Chemotherapy in Bladder Cancer Treatment | Dr. Petros Grivas
In this episode of OncoDaily, Dr. Petros Grivas joins host Chandler Park to discuss the…
Oct 5, 2024, 23:32 | Insight
AstraZeneca Revealed Positive Results for Muscle Invasive Bladder Cancer Patients at ESMO 2024
IMFINZI (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of…
Oct 4, 2024, 08:17 | Blog
Zainab Shinkafi-Bagudu: There is power in numbers
Zainab Shinkafi-Bagudu shared a post on LinkedIn by Creation.co adding: "The power and reach of…
Sep 30, 2024, 16:54 | Insight
Tom Powles: 1st perioperative immune therapy study to show an OS in bladder cancer
Tom Powles shared an article on X: "Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder…
Sep 24, 2024, 11:31 | Blog
Tom Powles: How does Sunniforcast data fit into the non-clear cell landscape
Tom Powles shared a post on X: ''How does Sunniforcast data fit into the non-clear…
Sep 21, 2024, 14:04 | Blog
Enrique Grande: Another practice changing trial in the back
Enrique Grande shared a post on X: ''NIAGARA is the first randomized trial to demonstrate…
Sep 20, 2024, 12:57 | Blog
Neeraj Agarwal: The 1st results of the ph3 Niagara trial of cisplatin + gemcitabine +/- durvalumab in MIBC
Neeraj Agarwal shared a post on X: "Breaking news (practice changing) from ESMO24, Tom Powles…
Sep 20, 2024, 12:55 | Insight
Tom Powles: The 1st disitimab Vedotin and pembro in HER 1-3 urothelial carcinomas
Tom Powles shared a post on X: "The 1st disitimab Vedotin (HER-2 MMAE ADC) and…
Sep 19, 2024, 15:48 | Insight
Tom Powles: The 1st perioperative immune therapy study to show an OS in bladder cancer
Tom Powles shared a post on X: “Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder…
Sep 19, 2024, 04:32 | Societies
Best of ESMO24
The ESMO Congress 2024 took place in Barcelona, from September 13 to 17, 2024, at…
Sep 17, 2024, 16:42 | Blog
Tom Powles: SUNNIFORCAST at ESMO24
Tom Powles shared a post on X: "SUNNIFORCAST at ESMO24 ipi/nivo vs VEGF based therapy…
Sep 17, 2024, 10:06 | Insight
Sumanta K. Pal: Important analysis of SWOG 1500 published just ahead of ESMO24
Sumanta K. Pal shared a post on X: "Huge congrats to Pedro C Barata, who drove…
Sep 16, 2024, 16:31 | Societies
40 Posts Not To Miss From ESMO24 Day 3
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…
Sep 16, 2024, 16:18 | Societies
Key Findings from the NIAGARA Trial at ESMO 2024
The results of the NIAGARA trial were recently presented at ESMO 2024. The NIAGARA trial,…
Sep 15, 2024, 12:53 | Blog
Sumanta Pal's highlights from ESMO24
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at the…
Sep 14, 2024, 17:15 | Societies
45 Posts not to miss from ESMO24 Day 1
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Sep 14, 2024, 15:38 | Insight
ESMO24 Day 1 highlights by Tom Powles
The ESMO Congress 2024 (ESMO24) is taking place from 13-17 September 2024, in Barcelona. ESMO24…
Sep 10, 2024, 14:54 | Blog
Tom Powles: Belzutifan for clear cell renal cancer
Tom Powles shared a post on X: “Belzutifan significantly outperformed Everolimus in heavily pretreated clear…
Sep 10, 2024, 05:00 | Blog
Tian Zhang: Lots of bladder cancer data coming at ESMO24
Tian Zhang shared a post on X by Tom Powles adding: "Lots of bladder cancer…
Sep 9, 2024, 14:16 | Blog
Tom Powles: Should Enfortumab Vedotin with Pembrolizumab be avoided due to baseline clinical conditions
Tom Powles shared a post on X, about recent paper published in ESMO Open: The…
Aug 27, 2024, 19:10 | Blog
Petros Grivas: Looking forward to a fantastic ESMO24
Petros Grivas shared a post on X by ESMO, adding: "Looking forward to a fantastic…
Aug 26, 2024, 21:30 | Blog
Tian Zhang: 3 weeks til ESMO24!
Tian Zhang shared a post by ESMO on X, adding the following: “T -3 weeks…
Aug 26, 2024, 20:08 | Insight
Tom Powles: Belzutifan significantly outperformed Everolimus in heavily pretreated clear cell renal cancer
Tom Powles, Professor of urology cancer at the University of London and the Director of…
Aug 14, 2024, 12:07 | Blog
Oncoinfluencers to Follow on Social Media: Dr. Tom Powles
We are excited to spotlight Dr. Tom Powles, a leading expert in urological oncology, as…
Aug 6, 2024, 03:43 | Blog
Tian Zhang: CtDNA to replace radiology for disease recurrence?
Tian Zhang posted on X: "Fiery discussion on minimal residual disease for bladder cancer —…
Aug 4, 2024, 17:13 | Insight
Shilpa Gupta: Community oncologists discuss the real world practice patterns in GU cancers at WorldGU24
Shilpa Gupta shared on X: “WorldGU24, An amazing session with The Uromigos, Tom Powles, Brian Rini…
Aug 4, 2024, 14:30 | Societies
8 Posts Not To Miss From GUWorld24!
The 2024 World Conference On Genitourinary Cancers (GUWorld24) took place from August 1st to 3rd…
Jul 30, 2024, 12:56 | Blog
Tian Zhang: Uromigos anticipating some lively discussions
Tian Zhang shared a post by Uromigos on X, adding: "See you next week at World GU,…
Jul 28, 2024, 13:01 | Insight
Brian Rini: Excited for our session with WorldGU24
Brian Rini, Chief of Clinical Trials at Vanderbilt University, shared a post by Uromigos on…
Jul 28, 2024, 08:32 | Blog
At ANZUP 24 Cristiane Bergerot presented a new HRQOL measure for patients with localized and metastatic RCC - Florez Lab
Florez Lab shared on X: "At ANZUP 24 Dr. Cristiane Bergerot presented a new HRQOL…
Jul 21, 2024, 09:13 | Insight
Sumanta K. Pal: Excellent review on kidney cancer from Tom Powles
Sumanta K. Pal shared on X a recent paper by Matthew Young et al. titled…
Jul 20, 2024, 18:07 | Blog
Tom Powles: More evidence that PD(L)1 re-challenge should be avoided in renal cancer
Tom Powles posted on X/Twitter: "More evidence that PD(L)1 re-challenge should be avoided in renal…
Jul 14, 2024, 21:15 | Blog
Sumanta K. Pal: Excellent use of Twitter polls to reconcile tough clinical scenarios
Sumanta K. Pal shared a post on X: ''Brilliant insights from Tom Powles, Barts Cancer Institute.…
Jul 14, 2024, 05:39 | Blog
Thomas Powles: An intratumoral micro-device releases small amounts of drugs locally to assess efficacy
Thomas Powles posted on X: "An intratumoral micro-device releases small amounts of drugs locally to…
Jul 13, 2024, 12:22 | Insight
Key Highlights from KCRS24 by Sumanta K. Pal
Kidney Cancer Research Summit or the KCRS24 was a conference held on 11th-12th July in Boston focused…
Jul 12, 2024, 13:32 | Societies
Insights from KCRS24 by Neeraj Agarwal
Kidney Cancer Research Summit or the KCRS24 was a conference held on 11th-12th July in…
Jul 10, 2024, 11:57 | Blog
The 2024 Uromigos Cup
Uromigos formed in early 2017 as a group of friends attempting to provide balanced, scientific content…
Jul 7, 2024, 14:06 | Blog
Christian Gratzke: Great to have Tom Powles at Uro Trials
Christian Gratzke, Urologic Surgeon and Chair at University of Freiburg, shared on X: "Great to have…
Jul 7, 2024, 04:49 | Insight
Harold J. Burstein: Important questions about 'getting to 2nd line therapy.'
Harold J. Burstein, Breast cancer specialist and professor at Dana Farber Cancer Institute, shared a…
Jul 6, 2024, 13:29 | Blog
ESMO - immune cell-related biomarkers in metastatic HNSCC
ESMO shared on LinkedIn: "Latest podcast. Annals of Oncology Editor in Chief Tom Powles talks to…
Jul 6, 2024, 08:45 | Insight
Tom Powles on RCC patients receiving ICI therapy
Tom Powles shared on X: “During the period of PD-1 inhibition availability for RCC in…
Jul 5, 2024, 05:41 | Blog
Abeid Athman: Joining ASCO had a huge role in shaping my career
Abeid Athman, Clinical Oncologist at Kenyatta University Hospital, shared on X: "It has been 5…
Jul 2, 2024, 11:12 | Blog
Enrique Grande: Fabulous and inspiring view of the short term future of advanced bladder cancer
Enrique Grande shared a post on X:                 …
Jul 1, 2024, 14:48 | Blog
Daniel Castellano: Great proposals in a urothelial cancer workshop at GUARD Symposium 2024
Daniel Castellano, Medical Oncologist at University Hospital October 12, shared on X: “Great discussion and…
Jul 1, 2024, 01:24 | Blog
Daniel Castellano: Biomarker selected bladder sparing preservation program is the future
Daniel Castellano, Medical Oncologist at University Hospital October 12, shared on X: "Excellent and clarifier…
Jun 26, 2024, 13:51 | Insight
Tom Powles: Durvalumab with neoadjuvant chemo then cystectomy in MIBC
Tom Powles shared on X: "Positive results from the NIAGARA Phase III trial showed durvalumab…
Jun 26, 2024, 03:43 | Blog
Roberto Iacovelli: Honour to have TIDE-A commented by Laurence Albiges, Tom Powles and Dr. Wells
Roberto Iacovelli shared a post on X: "Great honor to have TIDE-A commented by Laurence…
Jun 20, 2024, 05:06 | Blog
Pedro C Barata: Check out the wonderful editorial led by Jason Brown
Jason Brown, GU Oncologist at University Hospitals, shared a post by Pedro C Barata, GU Med Oncologist…
Jun 15, 2024, 07:36 | Blog
Tom Powles and Giorgio Bogani Discuss the Recently Published Study on Advanced or Recurrent Endometrical Cancer
The European Society for Medical Oncology (ESMO) posted on LinkedIn: “Latest podcast Annals of Oncology Editor-in-Chief…
Jun 6, 2024, 10:02 | Societies
Tom Powles: Great investigator-initiated study from LACOG and Fernando Maluf
Tom Powles, Director of Barts Cancer Center, shared a post on X: "40% response rate…
Jun 5, 2024, 12:44 | Blog
Tom Powles: Perhaps the most important long-term bladder cancer data at ASCO24
Tom Powles, Director of Barts Cancer Center, shared on X/Twitter: ''Perhaps the most important long-term…
Jun 1, 2024, 12:50 | Blog
Lennard YW Lee: We are now one of the leading cancer research infrastructure for personalised cancer vaccine trials
Lennard YW Lee, Associate Professor at the University of Oxford, shared on LinkedIn: "Feeling proud…
Jun 1, 2024, 10:00 | Insight
Tom Powles: TROPICS-4 in heavily pretreated bladder cancer missed OS
Tom Powles, Director of Barts Cancer Center, shared on X: “TROPICS-4 (sacituzumab, govitecan versus chemo) in…
May 28, 2024, 14:33 | Societies
Tom Powles: Final results for axitinib/avelumab in 1st line RCC at ASCO24
Tom Powles, Director of Barts Cancer Center, shared on X: "Final results for axitinib/avelumab in 1st…
May 28, 2024, 07:49 | Insight
Tom Powles: Renal cancer highlights at ASCO24 - KIM1 biomarker data stands out
Toni Choueiri shared a post by Tom Powles, Director of Barts Cancer Center, on X and…
12
All: 135 Posts: 1 - 100
Special Coverage